zydeligrems.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | ZYDELIG® (idelalisib) Official |
| Description | ZYDELIG® is a PI3Kδ inhibitor indicated Find information on ZYDELIG® (idelalisib). See full Prescribing Information, including BOXED |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 192.103.124.58 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
zydeligrems.com Valuation
|
US$1,274
Last updated: 2022-09-05 14:38:01
zydeligrems.com has Semrush global rank of 0. zydeligrems.com has an estimated worth of US$ 1,274, based on its estimated Ads revenue. zydeligrems.com receives approximately 147 unique visitors each day. Its web server is located in United States, with IP address 192.103.124.58. According to SiteAdvisor, zydeligrems.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,274 |
| Daily Ads Revenue | US$1 |
| Monthly Ads Revenue | US$35 |
| Yearly Ads Revenue | US$423 |
| Daily Unique Visitors | 9 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| zydeligrems.com. | A | 7199 | IP: 192.103.124.58 |
| zydeligrems.com. | NS | 86400 | NS Record: ns5.netnames.net. |
| zydeligrems.com. | NS | 86400 | NS Record: ns6.netnames.net. |
| zydeligrems.com. | NS | 86400 | NS Record: ns1.netnames.net. |
| zydeligrems.com. | NS | 86400 | NS Record: ns2.netnames.net. |
| zydeligrems.com. | MX | 86400 | MX Record: 20 relay2.netnames.net. |
| zydeligrems.com. | MX | 86400 | MX Record: 10 relay1.netnames.net. |
HtmlToTextCheckTime:2022-09-05 14:38:01
| Full Prescribing Information Important Safety Information Intended for US healthcare professionals only. Full Prescribing Information Important Safety Information Medication Guide View Healthcare Professional Site ZYDELIG ® is a PI3K δ inhibitor indicated for the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities. Limitations of use: ZYDELIG is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas. ZYDELIG is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas. PI3K δ =phosphatidylinositol 3-kinase. ZYDELIG ® AccessConnect ® Patient financial |
HTTP Headers
HTTP/1.1 200 OK Cache-Control: private Content-Length: 16865 Content-Type: text/html; charset=utf-8 X-AspNetMvc-Version: 5.2 X-AspNet-Version: 4.0.30319 Date: Thu, 23 Dec 2021 02:15:23 GMT |
zydeligrems.com Whois Information
Domain Name: ZYDELIGREMS.COM Registry Domain ID: 1859852906_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.corporatedomains.com Registrar URL: http://cscdbs.com Updated Date: 2021-05-18T05:24:50Z Creation Date: 2014-05-22T23:08:29Z Registry Expiry Date: 2022-05-22T23:08:29Z Registrar: CSC Corporate Domains, Inc. Registrar IANA ID: 299 Registrar Abuse Contact Email: domainabuse@cscglobal.com Registrar Abuse Contact Phone: 8887802723 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS1.NETNAMES.NET Name Server: NS2.NETNAMES.NET Name Server: NS5.NETNAMES.NET Name Server: NS6.NETNAMES.NET DNSSEC: unsigned >>> Last update of whois database: 2021-12-26T07:25:12Z <<< |